Global Generative Artificial Intelligence (AI) In Drug Discovery Market Revenue and CAGR Forecast Analysis 2025–2029
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Are The Future Growth Projections For The Generative Artificial Intelligence (AI) In Drug Discovery Market Size?
Over the past few years, the generative AI market for drug discovery has seen exceptional growth. It is projected to expand from $0.19 billion in 2024 to $0.25 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 30.6%. The historical growth can be linked to various factors including the escalating occurrence of chronic diseases, advancements in drug discoveries and clinical trials, greater integration of AI in healthcare and drug development, expansion of biotech industries, and increased government support.
The market size of generative artificial intelligence (AI) in drug discovery is predicted to witness remarkable growth in the coming years, soaring to $0.7 billion in 2029 with a compound annual growth rate (CAGR) of 28.8%. The projected growth during the forecast period is due to the increase in demand for cost-efficient drug discovery methods, fostering generative AI’s adoption. It’s further influenced by the escalating partnerships between market players, growing computational capacities, the incorporation of generative AI with other rising technologies, and speedy drug development. Emerging trends include incorporating generative AI with experimental biology, high-throughput screenings for expedited drug discovery, the advent of AI-driven platforms for repurposing drugs, and heightened acceptance of cloud-based AI solutions for joint drug discovery efforts.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16067&type=smp
Which Demand Drivers Are Strengthening The Generative Artificial Intelligence (AI) In Drug Discovery Market?
The surge in clinical trials is projected to boost generative AI development within the drug discovery industry. Clinical trials, involving human volunteers, evaluate new medical treatments or procedures for safety and efficacy, with the objective to accumulate scientific data regarding their appropriateness for human application. This surge is predominantly linked to progression in medical studies, escalated disease rates, regulatory transformations, globalization of clinical studies, patient advocacy and enlightenment, industry rivalry, technological breakthroughs, and available funding. Data from clinical trials feeds into generative AI models, accelerating drug discovery by forecasting interactions and establishing compounds. This combined approach facilitates personalized medicine, enhances treatment effectiveness, boosts patient results, and transforms the pharma sector. For example, as per ClinicalTrials.gov, a US clinical trial database, by the close of 2023, global registration of clinical trials reached 477,234, a rise from 437,512 trials registered in 2022. Hence, the escalating quantity of clinical trials is propelling the growth of generative AI in the drug discovery market.
What Segmentation Insights Are Provided In The Generative Artificial Intelligence (AI) In Drug Discovery Market Research?
The generative artificial intelligence (AI) in drug discoverymarket covered in this report is segmented –
1) By Type: Small Molecule; Large Molecule
2) By Technology: Deep Learning; Machine Learning; Reinforcement Learning; Molecular Docking; Quantum Computing
3) By End-User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutions; Contract Research Organizations (CROs); Other End-Users
Subsegments:
1) By Small Molecule: Drug Design And Optimization; Lead Discovery And Identification; Toxicology Prediction; Molecular Property Prediction; ADMET (Absorption, Distribution, Metabolism, Excretion, And Toxicity) Prediction
2) By Large Molecule: Protein Structure Prediction; Antibody Design; Biologics Optimization; Peptide Design; Biopharmaceutical Discovery And Optimization
Which Notable Trends Are Transforming The Generative Artificial Intelligence (AI) In Drug Discovery Market Outlook?
Leading businesses in the generative AI sector for drug discovery are creating high-tech tools powered by artificial intelligence to fast-track the discovery processes of drugs. These tools, enhanced by AI, hasten the development of drugs by smoothing the process of drug discovery, its design, and clinical trials while using predictive analytics and machine learning. They ultimately improve efficiency in identifying targets and in compound screening, such as AI-based virtual screening, preclinical development, regulatory compliance, and manufacturing procedures. To exemplify, Google Cloud, a cloud computing service from the USA and a branch of Google, launched two groundbreaking solutions driven by AI in May 2023. These solutions – the Target and Lead Identification Suite and the Multiomics Suite – are aimed to advance drug discovery and precision medicine in biotech, pharmaceutical, and public sector entities. The Target and Lead Identification Suite aids researchers in comprehending amino acid roles and forecasting protein structures, while the Multiomics Suite hastens the analysis and comprehension of genomic data, thereby making the creation of personalized treatments simpler.
Which Firms Are Driving Innovation Within The Generative Artificial Intelligence (AI) In Drug Discovery Market?
Major companies operating in the generative artificial intelligence (AI) in drug discovery market are Bayer AG, NVIDIA Corporation, Merck KGaA, IBM Research, Schrödinger Inc., Valo Health, BenevolentAI, XtalPi Inc., Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Exscientia, Atomwise Inc., InveniAI LLC, Healx, Aitia, Cloud Pharmaceuticals Inc., Optibrium, Aiforia, BioSymetrics Inc., Collaborations Pharmaceuticals Inc., MAbSilico, Reverie Labs, Standigm Inc., DeepMatter Group Limited, Variational AI Inc
Access The Complete Report Here:
Which Regional Markets Are Emerging As Key Hubs For The Generative Artificial Intelligence (AI) In Drug Discovery Market?
North America was the largest region in the generative AI in drug discovery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generative artificial intelligence (AI) in drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=16067&type=smp
Browse Through More Reports Similar to the Global Generative Artificial Intelligence (AI) In Drug Discovery Market 2025, By The Business Research Company
Generative Artificial Intelligence Ai In Sports Global Market Report 2025
Generative Artificial Intelligence In Development And Operations Devops Global Market Report 2025
Artificial Intelligence In Drug Discovery Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
